London
9 °C
Manchester
7 °C
Glasgow
Dublin
10 °C
Belfast
Washington
-1 °C
Denver
Atlanta
Dallas
10 °C
Houston Texas
New Orleans
El Paso
Phoenix
Los Angeles
-1 °C
-11 °C
-14 °C
24 °C
14 °C
Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22
NYSE - LSE
| RBGPF | 0% | 78.35 | $ | |
| CMSD | -0.3% | 23.25 | $ | |
| AZN | 0.17% | 90.18 | $ | |
| SCS | -0.56% | 16.14 | $ | |
| BCC | -1.66% | 73.05 | $ | |
| NGG | -0.66% | 75.41 | $ | |
| GSK | -0.33% | 48.41 | $ | |
| BTI | -1.81% | 57.01 | $ | |
| CMSC | -0.21% | 23.43 | $ | |
| RELX | -0.55% | 40.32 | $ | |
| RIO | -0.92% | 73.06 | $ | |
| BCE | 1.4% | 23.55 | $ | |
| JRI | 0.29% | 13.79 | $ | |
| BP | -3.91% | 35.83 | $ | |
| VOD | -1.31% | 12.47 | $ | |
| RYCEF | -0.34% | 14.62 | $ |
Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22
ORLANDO, FLORIDA / ACCESS Newswire / October 2, 2025 / RedChip Companies will host an investor webinar with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP)(NASDAQ:SXTPW), a pharmaceutical company focused on developing new medicines for vector-borne diseases, on October 22, 2025, at 4:15 p.m. ET. The event will feature 60 Degrees Pharmaceuticals' CEO Geoffrey Dow, PhD.
Dr. Dow will highlight the potential of ARAKODA® (tafenoquine), an FDA-approved antimalarial developed with the U.S. Army, and its expanding commercial footprint in the U.S. He will also outline the company's plan to expand FDA approval for tafenoquine to babesiosis-a growing tick-borne illness, incidence of which, management believes is vastly underrepresented by CDC estimates and for which there is no FDA-approved therapy. 60 Degrees Pharmaceuticals has two clinical trials (hospitalized babesiosis patients and relapsing patients) underway, and initiation of a third planned near-term.
60 Degrees Pharmaceuticals has Orphan Drug status for tafenoquine for babesiosis and patent exclusivity for the malaria indication through 2035.
A live Q&A session with management will follow the presentation.
To register for the free webinar, please visit: https://www.redchip.com/webinar/SXTP/88177419350
Questions can be pre-submitted to [email protected] or online during the live event.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of vector-borne diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of War and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-REDCHIP (733-2447)
[email protected]
--END--
SOURCE: RedChip Companies, Inc.
View the original press release on ACCESS Newswire
(Y.Harris--TAG)
